News - Kyorin Pharmaceuticals


Current filters:

Kyorin Pharmaceuticals

Popular Filters

Flutiform recommended for approval in Japan


UK drug delivery specialist Skyepharma (LSE SKP) revealed yesterday (July 31) that the Pharmaceutical…

Asia-PacificFlutiformKyorin PharmaceuticalsPharmaceuticalRegulationRespiratory and PulmonarySkyepharma

Astellas and Ambrx collaborate in up to $300 oncology deal; Teijin takes stake in Kyorin


Japanese drug major Astellas Pharma (TYO: 4503) has entered into a collaboration with venture capital…

AmbrxAstellas PharmaKyorin PharmaceuticalsLicensingMergers & AcquisitionsOncologyPharmaceuticalTeijin

Kyorin Pharma transfers Pekiron rights to Galderma


Japan's Kyorin Holdings (TYO: 4569), through its Kyorin Pharmaceuticals subsidiary, aiming to concentrate…

Asia-PacificDermatologicalsGaldermaKyorin PharmaceuticalsLicensingPekironPharmaceutical

SkyePharma partner Kyorin files for Flutiform approval in Japan


UK drug delivery specialist SkyePharma (LSE: SKP) says that its Japanese development and marketing partner…

Asia-PacificFlutiformKyorin PharmaceuticalsNapp PharmaceuticalsPharmaceuticalRegulationRespiratory and PulmonarySkyepharma

SkyePharma partner Kyorin completes Japanese Flutiform clinical program


UK drug delivery specialist SkyePharma (LSE: SKP) saw its shares leap nearly 11% to £76.50 last…

Asia-PacificFlutiformKyorin PharmaceuticalsPharmaceuticalRegulationResearchRespiratory and PulmonarySkyepharma

Back to top